Methods and compositions useful for inhibition of angiogenesis
AssigneeThe Scripps Research Institute
InventorsPeter Brooks, David A. Cheresh
Life of this patent
Estimating the term…
Abstract
The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin .alpha..sub.v .beta..sub.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing .alpha..sub.v .beta..sub.3 antagonists.
Claims114
A method of inducing solid tumor tissue regression in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist sufficient to inhibit neovascularization of a solid tumor tissue.
A method of inhibiting solid tumor tissue growth undergoing neovascularization in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist sufficient to inhibit solid tumor tissue growth.
A method for treating a patient with inflammed tissue in which neovascularization is occurring comprising administering to said patient a composition comprising a therapeutically effective amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist.
A method for treating a patient in which neovascularization is occurring in retinal tissue comprising administering to said patient a composition comprising a neovascularization-inhibiting amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist.
A method for treating a patient for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty comprising administering to said patient a composition comprising a therapeutically effective amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist.
A method of reducing blood supply to a tissue required to support new growth of said tissue in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an RGD-containing integrin .alpha..sub.v .beta..sub.3 antagonist sufficient to reduce said blood supply to said tissue.
Dependencies are inferred from the claim text.